[go: up one dir, main page]

AR058140A1 - Metodo de produccion proteica utilizando compuestos anti-senescencia - Google Patents

Metodo de produccion proteica utilizando compuestos anti-senescencia

Info

Publication number
AR058140A1
AR058140A1 ARP060104624A ARP060104624A AR058140A1 AR 058140 A1 AR058140 A1 AR 058140A1 AR P060104624 A ARP060104624 A AR P060104624A AR P060104624 A ARP060104624 A AR P060104624A AR 058140 A1 AR058140 A1 AR 058140A1
Authority
AR
Argentina
Prior art keywords
production method
cell culture
protein production
senescence
senescence compound
Prior art date
Application number
ARP060104624A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37873105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR058140(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR058140A1 publication Critical patent/AR058140A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

Se proporcionan mctodos para producir una proteína en cultivo celular que comprende un compuesto anti-senescencia, tal como el antioxidante carnosina. De acuerdo con las ensenanzas de la presente invencion, las células cultivadas en un medio de cultivo celular que comprende un compuesto anti-senescencia exhiben mayor viabilidad y productividad. Adicionalmente, los cultivos celulares cultivados en presencia de un compuesto anti-senescencia exhiben niveles reducidos de agregados de elevado peso molecular en el medio de cultivo celular.
ARP060104624A 2005-10-24 2006-10-23 Metodo de produccion proteica utilizando compuestos anti-senescencia AR058140A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72957305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
AR058140A1 true AR058140A1 (es) 2008-01-23

Family

ID=37873105

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060104624A AR058140A1 (es) 2005-10-24 2006-10-23 Metodo de produccion proteica utilizando compuestos anti-senescencia

Country Status (23)

Country Link
US (1) US20070110743A1 (es)
EP (1) EP1941026B1 (es)
JP (2) JP2009512459A (es)
KR (1) KR101402634B1 (es)
CN (1) CN101297027B (es)
AR (1) AR058140A1 (es)
AU (1) AU2006306433B2 (es)
BR (1) BRPI0617744A2 (es)
CA (1) CA2627003C (es)
CR (1) CR9897A (es)
DK (1) DK1941026T3 (es)
EC (1) ECSP088395A (es)
ES (1) ES2485374T3 (es)
IL (1) IL190550A (es)
NI (1) NI200800111A (es)
NO (1) NO20081622L (es)
PE (1) PE20070796A1 (es)
PL (1) PL1941026T3 (es)
PT (1) PT1941026E (es)
RU (1) RU2491347C2 (es)
SI (1) SI1941026T1 (es)
TW (1) TW200736397A (es)
WO (1) WO2007050498A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2463345C2 (ru) 2006-07-13 2012-10-10 Вайет Получение гликопротеинов
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
NZ592097A (en) 2008-10-20 2013-01-25 Abbott Lab Viral inactivation during purification of il-12 and il-18 antibodies
US8859235B2 (en) 2009-08-14 2014-10-14 Basf Se Methods in cell cultures, and related inventions, employing certain additives
US9012178B2 (en) 2010-08-05 2015-04-21 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
KR20130101034A (ko) * 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
TW201247874A (en) * 2011-05-25 2012-12-01 United Biomedical Inc Method for producing the activity of bone activating protein
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9206390B2 (en) 2012-09-02 2015-12-08 Abbvie, Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
KR102276326B1 (ko) * 2013-03-13 2021-07-13 앙테이스 에스.아. 피부 회춘을 위한 펩타이드 및 이것을 사용하는 방법
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
KR20210037745A (ko) * 2013-03-15 2021-04-06 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
AU2014337263B2 (en) 2013-10-16 2019-12-12 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN104398398A (zh) * 2014-10-27 2015-03-11 陈少威 一种细胞量子动力素(平衡剂)及其使用方法
MA40864A (fr) * 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
US10696735B2 (en) 2015-01-21 2020-06-30 Outlook Therapeutics, Inc. Modulation of charge variants in a monoclonal antibody composition
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN108350416A (zh) * 2015-11-09 2018-07-31 百时美施贵宝公司 操纵在cho细胞中产生的多肽的品质属性的方法
CN109153717A (zh) * 2016-01-06 2019-01-04 安口生物公司 减少单克隆抗体组合物中的高分子量物类、酸性电荷物类和片段
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
US20190112569A1 (en) * 2017-10-16 2019-04-18 Regeneron Pharmaceuticals, Inc. In Situ Raman Spectroscopy Systems and Methods for Controlling Process Variables in Cell Cultures
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
WO2025053166A1 (ja) * 2023-09-05 2025-03-13 味の素株式会社 培地組成物
TW202536166A (zh) * 2023-12-25 2025-09-16 日商武田藥品工業股份有限公司 細胞的培養方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1992009298A1 (en) 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
RU2245365C2 (ru) * 1994-01-03 2005-01-27 Генентек Инк. Тромбопоэтин
US5830761A (en) * 1995-06-07 1998-11-03 Genetics Institute, Inc. Medium and methods for culturing mammalian cho cells
RU2134120C1 (ru) * 1995-06-26 1999-08-10 Безруков Михаил Васильевич Средство для стабилизации пептидной связи в белковом препарате
WO1997008320A1 (en) * 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP4306813B2 (ja) * 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6146847A (en) * 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
JP4215172B2 (ja) * 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
RU2274643C2 (ru) * 2001-04-24 2006-04-20 Иннодженетикс Н.В. Выделенный оболочечный белок hcv, способ его получения и лекарство, вакцина, фармацевтическая композиция (варианты) его содержащие
AU2003300276B2 (en) * 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
PL1678208T3 (pl) * 2003-10-27 2013-09-30 Wyeth Llc Usuwanie agregatów o wysokiej masie cząsteczkowej z użyciem chromatografii na hydroksyapatycie
WO2005064013A1 (en) 2003-12-23 2005-07-14 Bart Janssen The use of carnosine metabolism-associated genes to determine genetic predisposition/susceptibility to diabetic nephropathy
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI374935B (en) * 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7426440B2 (en) * 2004-09-24 2008-09-16 Nutritional Bioscience Ltd. Repair and protection factor scoring method for bioactive agents

Also Published As

Publication number Publication date
ES2485374T3 (es) 2014-08-13
KR101402634B1 (ko) 2014-06-03
AU2006306433B2 (en) 2013-04-18
JP2013165728A (ja) 2013-08-29
CA2627003A1 (en) 2007-05-03
ECSP088395A (es) 2008-05-30
JP5907928B2 (ja) 2016-04-26
RU2491347C2 (ru) 2013-08-27
BRPI0617744A2 (pt) 2011-08-02
PL1941026T3 (pl) 2014-12-31
EP1941026B1 (en) 2014-06-04
AU2006306433A1 (en) 2007-05-03
IL190550A (en) 2017-01-31
PT1941026E (pt) 2014-07-31
NI200800111A (es) 2009-03-03
HK1120552A1 (en) 2009-04-03
JP2009512459A (ja) 2009-03-26
IL190550A0 (en) 2008-11-03
PE20070796A1 (es) 2007-08-15
US20070110743A1 (en) 2007-05-17
CN101297027B (zh) 2013-04-03
NO20081622L (no) 2008-06-18
CN101297027A (zh) 2008-10-29
DK1941026T3 (da) 2014-07-21
CA2627003C (en) 2018-08-28
WO2007050498A3 (en) 2007-07-12
EP1941026A2 (en) 2008-07-09
WO2007050498A2 (en) 2007-05-03
RU2008113220A (ru) 2009-12-10
TW200736397A (en) 2007-10-01
KR20080063365A (ko) 2008-07-03
SI1941026T1 (sl) 2014-07-31
CR9897A (es) 2008-07-29

Similar Documents

Publication Publication Date Title
AR058140A1 (es) Metodo de produccion proteica utilizando compuestos anti-senescencia
PA8778001A1 (es) Metodos de produccion de proteinas mediante la utilizacion de compuestos anti-senescencia
CO6501191A2 (es) Medio de cultivo celular para expresión de la proteina adamts
AR090822A1 (es) Composiciones de cultivo de celulas y metodos para la produccion de polipeptidos
CU20120006A7 (es) Producción de títulos elevados de poliovirus para la producción de vacunas
WO2008060541A3 (en) In vitro expansion of postpartum-derived cells using microcarriers
AR110864A2 (es) Procesos para cultivos celulares
WO2014143744A3 (en) Benzylisoquinoline alkaloids (bia) producing microbes, and methods of making and using the same
AR072376A1 (es) Induccion de floculacion en organismos fotosinteticos tales como algas
CR20110135A (es) INHIBIDORES DE cMET
CR11827A (es) Activadores de glucoquinasa
CO6531436A2 (es) Métodos de producción de glucoproteínas en cultivos de celulas de mamiferos usando glucocorticoides
WO2011133902A3 (en) Cell culture medium comprising small peptides
MX2013014937A (es) Cultivo de celulas de mamifero.
CO6440530A2 (es) Formulaciones de caldo de fermentación
ECSP14028704A (es) Métodos y composiciones para la modificación de adn objetivo dirigida por arn y para la modulación de la transcripción dirigida por arn
CO6680636A2 (es) Método para producir adamts13 recombinante en cultivo celular
EA201170024A1 (ru) Способы получения высокой плотности жизнеспособных клеток в культуре клеток млекопитающих
CY1121438T1 (el) Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης
CR20160307A (es) Composiciones para la restauración de células y métodos para la preparación y utilización de las mismas
MX2018006373A (es) Produccion de virus en cultivos celulares.
UY32732A (es) Medios para cultivo de células de mamíferos que comprenden sobrenadante del fraccionamiento de cohn y uso de los mismos
EA201170025A1 (ru) Способы повышения жизнеспособности и продукции культуры клеток
CY1112746T1 (el) Κρυοσυντηρηση ηπατοκυτταρων
CR8547A (es) Composiciones y metodos relacionados con el cultivo de celulas madre neurales con celulas estromales de medula osea

Legal Events

Date Code Title Description
FB Suspension of granting procedure